Minireviews
Copyright ©The Author(s) 2021. Published by Baishideng Publishing Group Inc. All rights reserved.
World J Clin Oncol. Jun 24, 2021; 12(6): 458-467
Published online Jun 24, 2021. doi: 10.5306/wjco.v12.i6.458
Chemotherapy-induced neurotoxicity in the treatment of gynecological cancers: State of art and an innovative approach for prevention
Ester Oneda, Chiara Abeni, Laura Zanotti, Elisabetta Zaina, Sara Bighè, Alberto Zaniboni
Ester Oneda, Chiara Abeni, Laura Zanotti, Elisabetta Zaina, Sara Bighè, Alberto Zaniboni, Department of Clinical Oncology, Fondazione Poliambulanza, Brescia 25124, Italy
Author contributions: Oneda E wrote the paper; Abeni C, Zanina E and Bighè S collected data; Zanotti L analyzed the data; Zaniboni A revised the paper.
Conflict-of-interest statement: Authors have no conflict of interest.
Open-Access: This article is an open-access article that was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution NonCommercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/Licenses/by-nc/4.0/
Corresponding author: Ester Oneda, MD, Doctor, Department of Clinical Oncology, Fondazione Poliambulanza, Via Bissolati 57, Brescia 25124, Italy. dott.ester.oneda@gmail.com
Received: February 26, 2021
Peer-review started: February 26, 2021
First decision: April 27, 2021
Revised: April 29, 2021
Accepted: June 4, 2021
Article in press: June 4, 2021
Published online: June 24, 2021
Core Tip

Core Tip: The association of carboplatin and paclitaxel is the standard chemotherapy regimen for ovarian cancer women. One of the most common and disabling side effect of this treatment is the peripheral neuropathy caused by paclitaxel, it can occur in 20% of patients and can last months and even years after the end of chemotherapy. In this review we collected the evidence from several studies with different schedules or formulation of paclitaxel and the systems of prevention and propose a mechanical way of prevention adopted in our center through the use of the cooling system of the hilotherm device.